MedPath

Astellas Pharma Global Development, Inc.

🇺🇸United States
Ownership
Subsidiary
Employees
-
Market Cap
-
Website

A Study of ASP2138 Given Before Surgery, Then Chemotherapy After Surgery, in People With Pancreatic Ductal Cancer

First Posted Date
2025-06-17
Last Posted Date
2025-06-17
Lead Sponsor
Astellas Pharma Global Development, Inc.
Target Recruit Count
25
Registration Number
NCT07024615

A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer

Phase 2
Not yet recruiting
Conditions
Prostate Cancer
Metastatic Castration-Resistant Prostate Cancer
Metastatic Hormone Sensitive Prostate Cancer
Interventions
First Posted Date
2025-06-05
Last Posted Date
2025-06-05
Lead Sponsor
Astellas Pharma Global Development, Inc.
Target Recruit Count
218
Registration Number
NCT07005154

A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer

Phase 3
Recruiting
Conditions
Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer
Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer
Metastatic Gastric Adenocarcinoma or Cancer
Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
Interventions
First Posted Date
2025-03-30
Last Posted Date
2025-06-18
Lead Sponsor
Astellas Pharma Global Development, Inc.
Target Recruit Count
500
Registration Number
NCT06901531
Locations
🇯🇵

National Cancer Center Hospital East, Kashiwa, Chiba, Japan

A Safety Study of Enfortumab Vedotin in Indian Adults With Urothelial Cancer

Phase 4
Not yet recruiting
Conditions
Metastatic Urothelial Carcinoma
Interventions
Drug: Enfortumab Vedotin
First Posted Date
2025-03-06
Last Posted Date
2025-03-06
Lead Sponsor
Astellas Pharma Global Development, Inc.
Target Recruit Count
100
Registration Number
NCT06862219

A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Chinese Women Going Through Menopause

Phase 2
Recruiting
Conditions
Hot Flashes
Interventions
Drug: Placebo
First Posted Date
2025-02-06
Last Posted Date
2025-06-29
Lead Sponsor
Astellas Pharma Global Development, Inc.
Target Recruit Count
150
Registration Number
NCT06812754
Locations
🇨🇳

Zhujiang Hospital of Southern Medical University, Guangzhou, Guangdong, China

🇨🇳

Beijing Hospital, Beijing, Beijing, China

🇨🇳

Capital Medical University (CMU) - Beijing Shijitan Hospital, Beijing, Beijing, China

and more 23 locations

A Study to Learn How Avacincaptad Pegol (Izervay™) is Used in Clinical Practice in People Who Have Geographic Atrophy

Recruiting
Conditions
Geographic Atrophy
Macular Degeneration
Interventions
Drug: Avacincaptad pegol (ACP)
First Posted Date
2025-01-17
Last Posted Date
2025-06-27
Lead Sponsor
Astellas Pharma Global Development, Inc.
Target Recruit Count
1000
Registration Number
NCT06779773
Locations
🇺🇸

Retinal Consultants Medical Group Inc, Sacramento, California, United States

🇺🇸

Colorado Retina Associates, PLLC, Lakewood, Colorado, United States

🇺🇸

Illinois Retina Associates, Oak Park, Illinois, United States

and more 23 locations

A Study of ASP1893 in Adults With Advanced CLDN6-positive Solid Tumors

Phase 1
Withdrawn
Conditions
Testicular Cancer
CLDN6-positive Solid Tumor
Ovarian Cancer
Endometrial Cancer
Metastatic or Locally Advanced Solid Tumor Cancer
Non-small Cell Lung Cancer
Interventions
First Posted Date
2024-11-08
Last Posted Date
2025-01-15
Lead Sponsor
Astellas Pharma Global Development, Inc.
Target Recruit Count
197
Registration Number
NCT06681870

A Study to Evaluate the Effects of ASP5502 in Healthy Adults and Adults With Primary Sjögren's Syndrome

Phase 1
Recruiting
Conditions
Healthy Volunteers
Sjögren's Syndrome
Interventions
Drug: Placebo
First Posted Date
2024-08-09
Last Posted Date
2025-05-08
Lead Sponsor
Astellas Pharma Global Development, Inc.
Target Recruit Count
132
Registration Number
NCT06544642
Locations
🇺🇸

Fortrea Clinical Research Unit Inc, Daytona Beach, Florida, United States

Experiment to Assess Preferences for Novel Hormonal Therapy and Androgen-deprivation Therapy in Prostate Cancer Patients

Completed
Conditions
Prostate Cancer
Interventions
Other: No Intervention
First Posted Date
2024-07-15
Last Posted Date
2025-05-06
Lead Sponsor
Astellas Pharma Global Development, Inc.
Target Recruit Count
374
Registration Number
NCT06500741
Locations
🇺🇸

Analysis Group, Inc., Boston, Massachusetts, United States

A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Women With Breast Cancer Who Are Having Hormone Therapy

Phase 3
Recruiting
Conditions
Hot Flashes
Interventions
Drug: Placebo
Drug: Aromatase inhibitor
First Posted Date
2024-06-04
Last Posted Date
2025-06-29
Lead Sponsor
Astellas Pharma Global Development, Inc.
Target Recruit Count
540
Registration Number
NCT06440967
Locations
🇨🇦

Site CA15002, Montreal, Quebec, Canada

🇨🇦

Site CA15001, Quebec City, Quebec, Canada

🇨🇦

Site CA15003, Sherbrooke, Quebec, Canada

and more 76 locations
© Copyright 2025. All Rights Reserved by MedPath